Upper Gastrointestinal Perforations: a Nationwide Registry-based Study
Launched by REGION STOCKHOLM · Nov 23, 2023
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how doctors in Sweden treat perforations, or holes, that can occur in the esophagus, stomach, or small intestine. These kinds of injuries can lead to serious health issues, and the study aims to gather information about the treatments used and how effective they are in helping patients survive. Researchers will look at data from adults who were treated for these perforations between January 2005 and August 2023 to improve future care.
To be eligible for this study, participants must be at least 18 years old and have suffered a perforation in the upper gastrointestinal tract. Children are not included in this study. While the trial is not currently recruiting participants, those who meet the criteria may be contacted in the future. The findings from this research could lead to better treatment options and improved outcomes for patients facing similar health challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age of at least 18 years
- • perforation in either oesophagus, stomach or small intestine
- • treatment carried out in Sweden
- • diagnosis set between January 2005 and August 2023
- Exclusion Criteria:
- • children
About Region Stockholm
Region Stockholm is a leading healthcare authority committed to advancing medical research and improving patient care through innovative clinical trials. As a sponsor, Region Stockholm collaborates with hospitals, research institutions, and industry partners to facilitate the development of new therapies and treatment protocols. With a focus on quality, safety, and ethical standards, the organization aims to enhance health outcomes for the diverse population of Stockholm and beyond, leveraging cutting-edge research to translate scientific discoveries into effective healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Patients applied
Trial Officials
Rebecka Ahl Hulme, MD, PhD
Principal Investigator
Karolinska University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported